Publication of 12-month outcomes reinforces SetPoint Medical’s pioneering role in advancing neuroimmune modulation as a new treatment paradigm for rheumatoid arthritis (RA)

SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, announced the publication of data from the RESET-RA study in Nature Medicine. The pivotal, double-blind, randomized, sham-controlled study evaluated the safety and efficacy of the SetPoint System, an implantable vagus nerve-targeted neuroimmune modulation device for adults living with moderately-to-severely active rheumatoid arthritis (RA) who are not adequately managed by—or cannot tolerate—existing advanced RA therapies, such as biological and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs).

Health Technology Insights: Nemluvio Shows Rapid Itch Relief and Sleep Benefits

“Neuroimmune modulation represents a major inflection point in the treatment history of rheumatoid arthritis,” said John Tesser, M.D., FACP, FACR, MACR, national principal investigator of RESET-RA study. “Publication of the RESET-RA study in Nature Medicine provides peer-reviewed recognition that further validates the quality and rigor of the clinical data that supported SetPoint System’s FDA approval.”

“The SetPoint System is designed to activate the body’s innate anti-inflammatory pathways that may be dysfunctional in people living with RA,” said David Chernoff, M.D., Chief Medical Officer of SetPoint Medical. “The RESET-RA study, built on over two decades of research and engineering, verified that neuroimmune modulation can deliver clinically meaningful and sustained improvements to those who continue to struggle with RA despite trying traditional therapeutic options.”

Health Technology Insights: Form Health Offers Clear, Predictable GLP-1 Coverage for Employers

RESET-RA results demonstrated clinically meaningful improvements and sustained efficacy through 12 months. Highlights from the published findings include:

Efficacy and durability outcomes:

  • Statistically significant and clinically meaningful improvement in ACR20 response, a composite measure of the effectiveness of RA treatments set forth by the American College of Rheumatology, at three months (p = 0.0209), with improving response rates of 50.0% at 6 months and 52.8% at 12 months in open-label follow-up.
  • Clinically relevant composite outcomes such as disease activity scores showed a similar trend with 77.3% achieving EULAR good/moderate response rates, 49.3% attaining DAS28-CRP (Disease activity score based on 28 joint count and CRP) low disease activity or remission, and 47.4% attaining CDAI (Clinical Disease Activity Index) low disease activity or remission after 12 months of treatment without the addition of biological DMARD or JAK inhibitor.
  • At 12 months, 75.2% of patients remained free from having an adjunctive biological DMARD or JAK inhibitor added to their stimulation therapy.
  • Outcome Measures in Rheumatology (OMERACT) Rheumatoid Arthritis MRI Scoring System (RAMRIS) demonstrated a 50% relative reduction in erosion progression in the treatment group compared to the control (p=0.016) from baseline to 3 months in a pre-specified subgroup of patients at higher risk for erosive damage.

Safety outcomes:

  • The safety evaluation was based on all available data at the time of reporting, with a mean implant duration of >700 days. No related-deaths or unanticipated adverse device effects occurred at any point during the trial. Overall, adverse events (AEs) occurred in a similar proportion of patients in both arms during the controlled period.
  • Related serious adverse events (rate=1.6%) were all perioperative within the first three months and resolved.
  • No new serious adverse events or safety concerns identified through other protocolized safety monitoring assessments were related to the device, procedure, or stimulation, in the open-label period of stimulation through 12 months.

Publication of the data in Nature Medicine builds on a series of recent milestones for SetPoint Medical, including FDA approval of the SetPoint System and the nation’s first patient to receive the FDA-approved device at Northwell Health’s North Shore University Hospital. The SetPoint System is currently available in select U.S. markets, with broader national expansion planned throughout 2026.

Health Technology Insights: FDA Approves Exdensur (Depemokimab) for Severe Asthma

To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com

Source- businesswire